Microsatellite instability (MSI) and mutations of BRAF and KRAS have been investigated as candidate biomarkers of “independent” prognostic value in patients with colorectal cancer for some time.1,2 Depending on tumor stage and treatment, their prognostic value seems to vary, but even in trials with similar populations and treatment the prognostic value is still controversial. Whether and how these 3 biomarkers are associated with outcome in patients with stage III colon cancer treated with combination leucovorin-calcium, fluorouracil, and oxaliplatin (FOLFOX)-based chemotherapy and how they influence each other are relevant research questions.
Klingbiel D, Tejpar S. Microsatellite Instability and BRAF and KRAS Mutations in Stage III Colon Cancer: Requirements for Accurate Prognosis Assessment. JAMA Oncol. 2016;2(5):653–654. doi:10.1001/jamaoncol.2015.5226
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: